Oncimmune Holdings plc
("Oncimmune" or the
"Company")
Investor Presentation via
Investor Meet Company
Oncimmune Holdings plc (AIM: ONC.L),
a leading autoantibody profiling company to the pharmaceutical and
biotechnology industry enabling precision medicine, is
pleased to announce that Martin Gouldstone, CEO, and Martin Hudson,
Finance Director, will provide a live presentation relating to the
unaudited interim results for the six months ended 29 February 2024
("H1 FY2024"), which are expected to be announced on Tuesday 21
May, via Investor Meet Company on 21 May 2024, 14:00
BST.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 20 May
2024, 09:00 BST, or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet Oncimmune via:
https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
Investors who already follow
Oncimmune on the Investor Meet Company platform will automatically
be invited.
For further information please
contact:
Oncimmune Holdings plc
|
|
contact@oncimmune.com
|
|
|
|
Cavendish
Capital Markets Limited (Nominated Adviser and Joint
Broker)
|
|
Geoff Nash, George
Dollemore, Trisyia Jamaludin (Corporate Finance)
Nigel Birks, Ondraya
Swanson (ECM)
+44 (0) 20
7220 0500
|
|
|
|
Zeus Capital
Limited (Joint Broker)
|
|
Dominic King, Victoria Ayton, Dan
Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
|
|
|
|
|
| |
Notes to
Editors
About
Oncimmune
Oncimmune is a precision medicine company,
specialising in analysing immune interactions through the
autoantibody profile. Taking a platform approach to generating
insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations
(CROs) to discover novel biomarkers for the development of more
targeted and effective therapies across many immune-mediated
diseases. Our mission at Oncimmune is to enable precision medicine.
We help our partners to discover novel biomarkers, drug targets and
predict treatment efficacy through the application of our platform.
We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of
experience in the field. Our aim is to make this an essential tool
in drug discovery and development.
Oncimmune is headquartered in the UK, with its
discovery and development facility based in Dortmund, Germany and a
business development team based in the US and Europe.
For more information, visit
www.oncimmune.com